Growth financing Claret Capital Partners specializes in growth debt and has demonstrated capacity to support scale across technology, life sciences, and impact sectors. This presents a sales opportunity to cross-sell debt facilities or refinancing options to portfolio companies approaching Series B+ growth, international expansion, or revenue acceleration.

Pan-European expansion Active and expanding presence in Europe with new teams in Paris and Berlin signals a readiness to partner with fast-growing tech and biotech firms across multiple EU markets. Target high-growth startups and scale-ups seeking on-the-ground European financing and regional advisory services.

Strategic sectors Track record across technology, life sciences, and impact sectors suggests opportunities with cohorts in AI, digital health, and sustainable tech. Align outreach to startups pursuing clinical trials, regulatory milestones, or AI-enabled customer insights that require growth capital and structured debt solutions.

Recent wins Recent investments in Neurent Medical, Cinclus Pharma, and EdgeTier illustrate appetite for healthcare tech, medtech, and AI-enabled customer insights. Leverage these success stories to approach similar high-potential companies in related sub-sectors for debt facilities, growth equity co-investments, or sponsor-friendly syndications.

Fundraising trajectory Final close in 2026 and ongoing pan-European platform expansion indicate a growing capacity to deploy larger facilities and longer-tenor debt across Europe. Use this to engage growth-stage companies seeking sizeable, flexible debt packages with regional support and local market intelligence.